Using AI to personalize treatment for head and neck cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to enhance treatment strategies for patients with head and neck squamous cell carcinoma (HNSCC) by utilizing artificial intelligence to analyze 18F-Fluorodesoxyglucose (FDG) PET imaging alongside clinical and histopathological data. The researchers will train a three-dimensional Convolutional Neural Network on a large retrospective cohort of patients who underwent either chemoradiation or surgery. The goal is to predict individual treatment outcomes and identify patients who are likely to have excellent or unfavorable responses to their respective treatments. This approach seeks to optimize and personalize treatment plans to mitigate serious side effects associated with current modalities.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All patients older than 18 years with diagnosed HNSCC, attending the Department of Radiooncology and Radiotherapy or the Department of Oral and Maxillofacial Surgery at Charité for a treatment with curative intension ( R(C)T or primary surgery / combined).
* All patients received as pretherapeutic diagnostic method a 18F-Fluorodesoxyglucose (FDG) positron emission tomography (PET) imaging

Exclusion Criteria:

* Patients with HNSCC who cannot be treated in a curative approach
* Patients with HNSCC treated in a curative approach but unable to receive FDG PET imaging before start of treatment
* Data from patients who have withdrawn their study consent

Where it's running

• Department of Radiooncology and Radiotherapy, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum
  Berlin, Germany Recruiting

Study contacts

• Study coordinator: Julian Weingärtner, Dr. med.
• Email: julian.weingaertner@charite.de
• Phone: 0030-450-657057

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TMV vaccine alone or with toripalimab for recurrent head and neck cancer

  This study tests a personalized TMV vaccine, alone and with toripalimab, in adults whose head and neck cancer has returned and is planning salvage surgery.

  Recruiting Phase 1 Metaclipse Therapeutics Corporation · Houston, Texas · NCT07898124

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• TS-104: a first-in-human, dose-escalation study for advanced solid tumors

  This study tests TS-104, a peptide-drug conjugate, as a single therapy in adults with advanced solid tumors like NSCLC, HNSCC, esophageal, gastric, ovarian, or endometrial cancer to see if it is safe and tolerable and whether it shows any benefit.

  Recruiting at 3 sites Phase 1 TwoStep Therapeutics, Inc. · Maumee, Ohio and 2 other locations · NCT07814248

• Intratumoral fluorescent nivolumab before surgery in head and neck cancer

  This study tests injecting fluorescently labeled nivolumab directly into head and neck tumors to see if it is safe and whether it reaches nearby lymph nodes before surgical removal.

  Recruiting Early Phase 1 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07741565

• SKB571 in recurrent or metastatic head and neck cancer in adults

  This study tests SKB571, alone or with Pembrolizumab and platinum chemotherapy, to see if it helps adults with recurrent or metastatic head and neck cancer.

  Recruiting at 2 sites Phase 2 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Chengdu and 1 other locations · NCT07668154

• Proton versus photon treatment for squamous cell cancers of the head and neck

  This trial will test whether proton radiation or standard photon radiation leads to less long-term dry mouth, swallowing problems, pain, and speech issues in people aged 40 and older with squamous cell cancers of the oral cavity, oropharynx, hypopharynx, or larynx treated with curative radiotherapy.

  Recruiting Phase 3 Oslo University Hospital · Bergen and 3 other locations · NCT07580300

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.